Singapore, 18 April 2024— Horizon Quantum Computing, a company building software development tools for quantum computers, today announced that it is establishing a first-of-a-kind testbed for integrating quantum computing hardware with...
Panacos was engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent serious infectious disease. Its lead antiviral product was PA-457, which at the time was the first in a new class of drugs to treat HIV infection. Pappas Ventures teamed up with Ampersand Ventures to take Panacos public via a reverse merger with V.I. Technologies in 2005.
The rights to Panacos’s HIV program were acquired by Myriad Pharmaceuticals in 2009.
Panacos Pharmaceuticals
Watertown, MA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.